As of October 8, 2026, Iambic Therapeutics has proposed an IPO of 9,375,000 shares at $15 to $17 per share. Its first amended S-1, filed that day, adds these terms to the registration statement first filed on September 21. Iambic has applied to list on the Nasdaq Global Select Market as IAM, and the offering depends on listing approval. The prospectus is preliminary: its final price and share-delivery date remain blank. J.P. Morgan, Jefferies, BofA Securities and Citigroup are the underwriters. Segmara does not sell, broker or arrange Iambic shares and does not predict a pricing or listing date.
Segmara is an independent research site. Segmara does not sell, broker, or arrange share purchases. Nothing here is investment advice.
Key points
What changed in the October 8 filing
The amended S-1 proposes 9,375,000 shares at $15 to $17 each, replacing the blank offering terms in the original September 21 filing. The underwriters also have a 30-day option to buy up to 1,406,250 additional shares.
Iambic has applied to list on the Nasdaq Global Select Market under IAM. The prospectus remains subject to completion, the offering depends on listing approval, and the final price and share-delivery date are blank. The proposed range does not establish a first trading date.
What the filing says about IAM1363
IAM1363 is an oral small-molecule inhibitor of HER2. The amended S-1 describes an ongoing, open-label Phase 1/1b basket trial in patients with advanced HER2-altered solid tumors.
Iambic says it anticipates starting a registrational trial as early as 2027, subject to regulatory feedback. That is the company's plan, not a trial result or a regulatory decision.
Use of proceeds and finances
Iambic estimates net proceeds of $135.0 million at the assumed $16 midpoint, after underwriting discounts, commissions and offering expenses, without the additional-share option. It plans to use the proceeds and existing cash for IAM1363, IAM217 and IAM-C1 development, its research platform, working capital and other corporate purposes.
The amended S-1 reports net losses of $77.3 million in 2025 and $50.1 million in the first half of 2026, with an accumulated deficit of $245.3 million at June 30, 2026.
AI-ready data summary
A structured extraction layer for this article: catalogue numbers, price context, chart values, and route-specific facts that search and AI systems can read directly from the page.
Metric
Value
Context
Canonical route
/blog/when-will-iambic-therapeutics-ipo
Stable URL path for AI and search extraction.
Article title
When Will Iambic Therapeutics IPO? $15 to $17 Proposed Range
Main page topic.
Attached public sources
3
Number of citation links rendered at the bottom of the article.
Segmara listed companies
51
Live private-company listings in the public catalogue.
Priced listings
37
Catalogue listings with visible indicative or direct marks.
Listings without an indicative price
14
Catalogue listings where a public price is intentionally not invented.
Data fingerprint chart
Visible pricing coverage72%
37 of 51 listings show a mark
Stage
Timing
Price / valuation signal
Interpretation
Chart metric
Score
Interpretation
Visible pricing coverage
72 / 100
37 of 51 listings show a mark
Analytical lens
Search intent
Searches like 'When Will Iambic Therapeutics IPO? $15 to $17 Proposed Range' are research questions: what a filing or a company statement confirms, what has only been reported, and what is still unknown.
What counts as a listing step
For an IPO, the primary record is a registration statement filed with the securities regulator of the listing market, such as an S-1 or F-1 on SEC EDGAR for a US listing. Funding rounds, valuations and secondary-market prices are context, not listing steps.
Segmara role
Segmara is an independent research site. It does not sell, broker, or arrange share purchases, and nothing on this page is investment advice.
How a company reaches a US listing
The SEC filing trail
DraftThe company can first submit a draft registration statement (DRS) for confidential SEC review.
S-1 or F-1The registration statement goes public on SEC EDGAR: Form S-1, or Form F-1 for many foreign companies. A company that used a draft must file publicly at least 15 days before its roadshow.
AmendmentsS-1/A or F-1/A amendments answer SEC comments, and one of them adds the expected price range.
PricingOnce the SEC declares the registration effective, the company sets the price with its underwriters and files the final prospectus, usually a 424B4.
First tradeThe shares start trading on the exchange named in the prospectus, such as Nasdaq or the NYSE.
Segmara Pro checks SEC EDGAR for Iambic Therapeutics filings every weekday and posts an alert in the members forum when one of these public filings appears. You can also check yourself with EDGAR full-text search.
Iambic filed Amendment No. 1 to its S-1 on October 8, 2026, proposing 9,375,000 shares at an expected $15 to $17 per share.
The proposed Nasdaq Global Select Market symbol is IAM. Listing approval is a condition of the offering; the preliminary prospectus leaves the final price and share-delivery date blank.
At the assumed $16 midpoint, Iambic estimates net proceeds of $135.0 million after offering costs, excluding the underwriters' option. This is an estimate, not money already raised.
Risk notes
Rumor risk: unofficial dates, valuations, or funding details circulating on social media or forums are frequently wrong or outdated and should not be treated as confirmation of anything.
Illiquidity risk: any private-market interest, indicative marks, or pre-IPO share arrangements in a company that has not listed can be difficult to exit and may not reflect a tradable price.
Timing risk: a company can pause, restart, or abandon IPO preparation at any stage, including after a confidential or public filing, so no step before pricing guarantees a listing.
Segmara Pro: a weekly IPO brief plus SEC filing alerts for 60+ companies, including Iambic Therapeutics, from automated EDGAR checks every weekday, posted in the members forum; 7-day free trial, then $15 a month (plus any applicable tax). Research only, no share sales.
Can retail investors track private-company shares on Segmara?
Yes. The free pre-IPO tracker sends indicative marks by email, with no card and no documents. Segmara does not sell, broker, or arrange share purchases.
Why was this market historically hard for retail investors to reach?
Private-company share access has often moved through private equity firms, venture funds, insiders, institutions, and relationship-driven secondary networks. Segmara makes research simpler: anyone can follow named private companies for free, by email.
What is the easiest next step?
Open the free pre-IPO tracker first, email only. The IPO calendar is free, and Segmara Pro adds a weekly IPO brief.
Has Iambic Therapeutics set an IPO date?
The October 8, 2026 preliminary prospectus does not specify a share-delivery date or final IPO price. It proposes a $15 to $17 range, but that does not confirm a first trading date.
What is Iambic's proposed IPO price?
The October 8 amended S-1 proposes 9,375,000 shares at $15 to $17 per share. Those terms are preliminary and may change; the $16 midpoint is an assumption used in the filing's estimates, not a final price.
What stage is IAM1363 in?
The amended S-1 describes an ongoing Phase 1/1b basket trial in advanced HER2-altered solid tumors. Iambic anticipates a registrational trial as early as 2027, subject to regulatory feedback.
Can I buy Iambic Therapeutics shares through Segmara?
No. Segmara is a research site and does not sell, broker or arrange Iambic shares before or after an IPO. The company's SEC filings are the primary record of the proposed offering.
Next step
Track private-market prices free.
If this article helped explain Iambic Therapeutics, start with the free tracker: indicative pre-IPO marks by email. No card, no documents, no brokerage account.
Segmara is an independent research site. Segmara does not sell, broker, or arrange share purchases.